Audited Financial Results and recommendation of final dividend for financial year 2025-26
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported strong FY2025-26 results with consolidated revenue growing 37% to Rs 2,023 crore from Rs 1,477 crore. Profit after tax jumped 40% to Rs 364 crore from Rs 260 crore, driven by robust growth across all geographies — Europe revenue up 57%, USA/North America up 69%. The Board recommended a final dividend of Rs 34 per share (340%). An exceptional gain of Rs 76.4 crore from sale of investment property in Hyderabad was recorded. Statutory auditors MSKA & Associates issued an unmodified opinion with no concerns. The company also announced a Rs 143.4 crore capacity expansion at its Bonthapally Unit 1 (120.5 KL addition in 12-18 months) to meet growing customer demand. Finance costs nearly tripled to Rs 23.9 crore due to increased borrowings.
Strong operational performance with 40% PAT growth and positive dividend signal shareholder-friendly policy. The capacity expansion investment indicates management confidence in sustained demand growth. Unmodified auditor opinion with no going concern issues is reassuring.